CA1296640C - Melange special de lipides pour la fluidisation de membranes - Google Patents
Melange special de lipides pour la fluidisation de membranesInfo
- Publication number
- CA1296640C CA1296640C CA000514674A CA514674A CA1296640C CA 1296640 C CA1296640 C CA 1296640C CA 000514674 A CA000514674 A CA 000514674A CA 514674 A CA514674 A CA 514674A CA 1296640 C CA1296640 C CA 1296640C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- weight
- glycerides
- neutral lipids
- phospholipids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 112
- 150000002632 lipids Chemical class 0.000 title claims abstract description 94
- 239000012528 membrane Substances 0.000 title claims abstract description 59
- 238000005243 fluidization Methods 0.000 title abstract description 13
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 40
- 230000007935 neutral effect Effects 0.000 claims abstract description 36
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 34
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 30
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 29
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims abstract description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 34
- 230000001965 increasing effect Effects 0.000 claims description 16
- 235000012000 cholesterol Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 150000003626 triacylglycerols Chemical class 0.000 claims description 12
- 102000002322 Egg Proteins Human genes 0.000 claims description 11
- 108010000912 Egg Proteins Proteins 0.000 claims description 11
- 235000013345 egg yolk Nutrition 0.000 claims description 11
- 210000002969 egg yolk Anatomy 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 description 57
- 235000005911 diet Nutrition 0.000 description 21
- 230000037213 diet Effects 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 4
- 238000000429 assembly Methods 0.000 description 4
- 230000000712 assembly Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- LYQFWZFBNBDLEO-UHFFFAOYSA-M caesium bromide Chemical compound [Br-].[Cs+] LYQFWZFBNBDLEO-UHFFFAOYSA-M 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000002297 mitogenic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000003617 erythrocyte membrane Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- BOBLSBAZCVBABY-WPWUJOAOSA-N 1,6-diphenylhexatriene Chemical compound C=1C=CC=CC=1\C=C\C=C\C=C\C1=CC=CC=C1 BOBLSBAZCVBABY-WPWUJOAOSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 239000012051 hydrophobic carrier Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000428533 Rhis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000008747 mitogenic response Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75927085A | 1985-07-26 | 1985-07-26 | |
| US759,270 | 1985-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1296640C true CA1296640C (fr) | 1992-03-03 |
Family
ID=25055034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000514674A Expired - Lifetime CA1296640C (fr) | 1985-07-26 | 1986-07-25 | Melange special de lipides pour la fluidisation de membranes |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0213724A1 (fr) |
| JP (1) | JPS6284028A (fr) |
| AU (1) | AU594066B2 (fr) |
| CA (1) | CA1296640C (fr) |
| FI (1) | FI863050L (fr) |
| NO (1) | NO862999L (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10177193B2 (en) | 2014-05-27 | 2019-01-08 | Commissariat à l'énergie atomique et aux énergies alternatives | Array of mesa photodiodes with an improved MTF |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857514A (en) * | 1985-09-17 | 1989-08-15 | Yeda Research And Development Company, Ltd. | Virus inactivation |
| US4812314A (en) * | 1986-02-24 | 1989-03-14 | Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization | Lipid replacement therapy |
| US5043329A (en) * | 1987-02-17 | 1991-08-27 | Board Of Regents, University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract |
| US4918063A (en) * | 1987-02-17 | 1990-04-17 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract |
| US5260284A (en) * | 1987-02-17 | 1993-11-09 | Board Of Regents, The University Of Texas System | Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy |
| US4950656A (en) * | 1987-02-17 | 1990-08-21 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract |
| US5032585A (en) * | 1987-02-17 | 1991-07-16 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy |
| AU618972B2 (en) * | 1987-10-06 | 1992-01-16 | Houston Biotechnology Incorporated | Phosphatidyl treatment of viral disease |
| ES2052066T3 (es) * | 1988-10-31 | 1994-07-01 | Sandoz Nutrition Ltd | Mejoras en o relacionadas con compuestos organicos. |
| DE68903930T2 (de) * | 1988-11-23 | 1993-05-19 | Abbott Lab | Lipidemulsion zur behandlung von aids. |
| CA2083171C (fr) * | 1990-05-18 | 2002-09-10 | Kurashima Kazuyoshi | Antasthmatique |
| US5231090A (en) * | 1990-07-30 | 1993-07-27 | University Of Miami | Treatment for hypercholesterolemia |
| US5319116A (en) * | 1992-02-12 | 1994-06-07 | Gary Viole | Lecithin fractions and dilutions, methods for their preparation and pharmacological uses thereof |
| US7208180B2 (en) | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
| US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
| CN106860705A (zh) * | 2017-03-27 | 2017-06-20 | 成都海青生物科技有限公司 | 一种治疗痰淤藴热所致小儿智能低下的中药组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2556592C2 (de) * | 1975-12-16 | 1986-10-09 | A. Nattermann & Cie GmbH, 5000 Köln | Arzneimittelzubereitungen auf Basis öliger Lösungen von Phospholipiden |
| JPS55118419A (en) * | 1979-03-05 | 1980-09-11 | Toyama Chem Co Ltd | Antihemolytic composition consisting of fat emulsion and immunizator and carcinostatic agent containing the same |
| JPS6030652B2 (ja) * | 1979-05-07 | 1985-07-17 | 株式会社ミドリ十字 | 静脈注射用脂肪乳剤 |
| DE3028074C2 (de) * | 1980-07-22 | 1983-12-08 | Kurt Kampffmeyer Mühlenvereinigung KG, 2000 Hamburg | Verfahren zur Herstellung eines lecithinhaltigen Produktes |
| DE3042365C2 (de) * | 1980-11-10 | 1987-01-29 | Extrakta Strauss GmbH, 2000 Hamburg | Flüssige, lecithinhaltige einphasige Mehrstoffsysteme und Verfahren zu ihrer Herstellung |
| IL63734A (en) * | 1981-09-04 | 1985-07-31 | Yeda Res & Dev | Lipid fraction,its preparation and pharmaceutical compositions containing same |
| DE3470277D1 (en) * | 1984-01-11 | 1988-05-11 | Von Mletzko Armin | Dietetic composition |
| IT1176916B (it) * | 1984-10-10 | 1987-08-18 | Elvira Pistolesi | Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica |
-
1986
- 1986-07-25 AU AU60579/86A patent/AU594066B2/en not_active Ceased
- 1986-07-25 FI FI863050A patent/FI863050L/fi not_active Application Discontinuation
- 1986-07-25 CA CA000514674A patent/CA1296640C/fr not_active Expired - Lifetime
- 1986-07-25 NO NO862999A patent/NO862999L/no unknown
- 1986-07-25 EP EP86305736A patent/EP0213724A1/fr not_active Ceased
- 1986-07-25 JP JP61175432A patent/JPS6284028A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10177193B2 (en) | 2014-05-27 | 2019-01-08 | Commissariat à l'énergie atomique et aux énergies alternatives | Array of mesa photodiodes with an improved MTF |
Also Published As
| Publication number | Publication date |
|---|---|
| FI863050A7 (fi) | 1987-01-27 |
| AU6057986A (en) | 1987-01-29 |
| FI863050L (fi) | 1987-01-27 |
| FI863050A0 (fi) | 1986-07-25 |
| NO862999L (no) | 1987-01-27 |
| AU594066B2 (en) | 1990-03-01 |
| EP0213724A1 (fr) | 1987-03-11 |
| JPS6284028A (ja) | 1987-04-17 |
| NO862999D0 (no) | 1986-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1296640C (fr) | Melange special de lipides pour la fluidisation de membranes | |
| EP0074251B1 (fr) | Nouvelle fraction de lipides, sa préparation et compositions pharmaceutiques la contenant | |
| US5152923A (en) | Process for the production of a nanoemulsion of oil particles in an aqueous phase | |
| US5043164A (en) | Blood-stable, cholesterol-free liposomes | |
| EP0161445B1 (fr) | Complexe hydrosoluble d'un médicament et procédé pour sa préparation | |
| US5023271A (en) | Pharmaceutical microemulsions | |
| DE69733966T2 (de) | Feste lipidzusammensetzungen von lipophilen verbindungen zur verbesserten oralen bioverfügbarkeit | |
| AU2004273700C1 (en) | Stabilized formulations of phosphatidylserine | |
| EP0804239B1 (fr) | Medicament anti-stress, anti-deficience et anti-vieillissement et son procede de fabrication | |
| JPH08208486A (ja) | スタウロスポリン誘導体の静脈内投与のための医薬組成物 | |
| Li et al. | The preparation of Cistanche phenylethanoid glycosides liquid proliposomes: Optimized formulation, characterization and proliposome dripping pills in vitro and in vivo evaluation | |
| JPH0523135A (ja) | Ａｃａｔ阻害剤 | |
| EP0416527A2 (fr) | Préparations de liposomes contenant des prostaglandines | |
| JPH01135720A (ja) | 神経線維再生剤 | |
| JPH07503014A (ja) | 癌の治療におけるカロチノイド類の処方及び用法 | |
| AU2016700A (en) | A pharmaceutical composition comprising cyclosporin in a lipid carrier | |
| CN114588109A (zh) | 辅酶q10乳剂及其制备方法和用途 | |
| JPH06116149A (ja) | 神経修復剤 | |
| Phillips et al. | Phospholipid and phospholipid fatty acid and aldehyde composition of red cells of patients with abetalipoproteinemia (acanthocytosis): Evidence for essential fatty acid deficiency in man | |
| JPS648601B2 (fr) | ||
| JP3058926B2 (ja) | ユビデカレノン含有組成物およびその調製方法 | |
| EP0933080A1 (fr) | Agent curatif ou preventif de l'hyperlipemie | |
| CN107184550B (zh) | 一种前列地尔注射液的制备方法 | |
| Butikofer et al. | Erythrocyte phospholipid organization and vesiculation in hereditary high red cell membrane phosphatidylcholine hemolytic anemia | |
| Spencer | Adenine Nucleotide Translocation in Rat Liver Mitochondria: Calcium Stimulation and the Involvement of Phospholipids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed | ||
| MKLA | Lapsed |
Effective date: 20010305 |